- Home
- SBGI vs COLL Comparison
SBGI vs COLL Comparison
Compare SBGI & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SBGI
- COLL
- Stock Information
- Founded
- SBGI 1986
- COLL 2002
- Country
- SBGI United States
- COLL United States
- Employees
- SBGI N/A
- COLL N/A
- Industry
- SBGI Broadcasting
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- SBGI Industrials
- COLL Health Care
- Exchange
- SBGI Nasdaq
- COLL Nasdaq
- Market Cap
- SBGI 1.1B
- COLL 1.1B
- IPO Year
- SBGI 1995
- COLL 2015
- Fundamental
- Price
- SBGI $15.99
- COLL $29.49
- Analyst Decision
- SBGI Buy
- COLL Strong Buy
- Analyst Count
- SBGI 5
- COLL 6
- Target Price
- SBGI $20.10
- COLL $42.00
- AVG Volume (30 Days)
- SBGI 234.8K
- COLL 476.0K
- Earning Date
- SBGI 02-26-2025
- COLL 02-20-2025
- Dividend Yield
- SBGI 6.22%
- COLL N/A
- EPS Growth
- SBGI N/A
- COLL 757.11
- EPS
- SBGI N/A
- COLL 2.16
- Revenue
- SBGI $3,370,000,000.00
- COLL $599,245,000.00
- Revenue This Year
- SBGI $15.03
- COLL $13.20
- Revenue Next Year
- SBGI N/A
- COLL $17.63
- P/E Ratio
- SBGI N/A
- COLL $13.59
- Revenue Growth
- SBGI 3.12
- COLL 9.62
- 52 Week Low
- SBGI $11.13
- COLL $28.75
- 52 Week High
- SBGI $18.45
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- SBGI 36.54
- COLL 41.27
- Support Level
- SBGI $15.95
- COLL $28.75
- Resistance Level
- SBGI $17.62
- COLL $31.06
- Average True Range (ATR)
- SBGI 0.67
- COLL 1.04
- MACD
- SBGI -0.23
- COLL 0.03
- Stochastic Oscillator
- SBGI 8.57
- COLL 30.96
About SBGI Sinclair Inc.
Sinclair Inc. is the owner-operator of the second largest portfolio of television stations in the United States, with 185 full power stations in 86 markets. Of the firm's roughly 600 channels, 150 are affiliated with the four national broadcasters—Fox, ABC, CBS, and NBC—with over 80 other channels aligned with The CW (Nexstar) and MyNetworkTV (Fox). Sinclair owns the Tennis Channel and stakes in Marquee Sports Network and YES Network, providing their content to pay-TV distributors.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.